Barbara Boughton | Authors

Articles

Advanced Melanoma Responds Well to Pembrolizumab/Ipilimumab Combination

November 25, 2015

A regimen of pembrolizumab (Keytruda) and low-dose ipilimumab (Yervoy) was effective, and tolerable, for patients with advanced melanoma, according to results from the phase Ib KEYNOTE-029 clinical trial presented by lead investigator Georgina Long, BSc, PhD, MBBS.